Developing Guidelines and Competencies for the Training of Psychedelic Therapists

Phelps situates this paper in the context of a renewed ‘‘renaissance’’ of clinical research on psychedelic-assisted psychotherapy and argues that, despite substantial outcome-focused evidence since the 1950s and especially in the last 20 years, therapist variables have been relatively neglected. Earlier decades produced extensive clinical and conference literature showing strong clinical effects for substances such as LSD, mescaline, psilocybin and, more recently, MDMA, but political and regulatory restrictions curtailed systematic inquiry into therapist competencies. Contemporary FDA-directed Phase I–III research prioritises standardised protocols and control of therapist effects, which has limited scholarship about which therapist qualities and training elements matter for optimal psychedelic-assisted care. The paper sets out to fill that gap by reviewing the extant (though sparse) literature, clinical trial reports, treatment manuals and historical writings to compile a set of core therapist competencies for psychedelic-assisted psychotherapy and to propose curricular domains for training. Phelps presents six umbrella competencies and twelve curricular domains as a first synthesis intended to inform future training, empirical inquiry, and ethical discussion as legal and clinical access to these therapies evolves.

This article is a narrative review and conceptual synthesis rather than a systematic meta-analysis. Phelps draws on historical accounts from the 1950s–1960s, recent clinical trial reports (notably psilocybin and MDMA studies conducted by groups at Johns Hopkins, MAPS, NYU, UCLA and others), treatment manuals (for example MAPS and Usona guides), and ethical codes developed by organisations such as the Council on Spiritual Practices. The extracted text does not provide a clear, reproducible search strategy, inclusion/exclusion criteria, databases searched, or formal risk-of-bias assessment. The approach combines three strands of source material: (a) summaries of contemporary clinical outcome studies to ground the discussion of participant experiences and therapeutic effects; (b) historical and ethnographic material on ceremonial and clinical use of psychedelics to inform contextual knowledge; and (c) treatment manuals, professional codes, and published commentaries to identify recurring descriptions of therapist qualities and training practices. From that material, the author synthesises six core competencies for ‘‘therapist guides’’ and delineates twelve curricular domains intended for training programmes. Where specific procedural or empirical details were essential (for example, examples of training practices used by MAPS, Heffter, Usona, CIIS and GTT), these are cited illustratively rather than subjected to formal comparative analysis.

Phelps first summarises contemporary clinical findings that inform what therapist competencies might be needed. For psilocybin, published studies from Johns Hopkins and other groups showed that high-dose sessions often occasion ‘‘mystical-type’’ experiences judged by participants as among their most personally and spiritually significant events; one Hopkins cohort reported that 94% of volunteers rated at least one session among their top-five spiritually significant experiences at long-term follow-up. Small pilot trials reported substantial clinical gains: in a smoking-cessation pilot, 12 of 15 participants were abstinent at 6 months (with 67% abstinent at 12 months in a follow-up report); trials in patients with life-threatening cancer showed reductions in anxiety, depression and death anxiety with clinically significant improvements sustained at 6 months for about 80% of participants. A trial of moderate-dose psilocybin in 29 cancer-related distress patients produced rapid, robust and enduring antidepressant and anxiolytic effects, and the authors reported that mystical experience mediated therapeutic benefit. For MDMA, Phelps highlights a Phase II PTSD trial in which 83% of participants who received MDMA-assisted psychotherapy no longer met PTSD diagnostic criteria at two months post-treatment compared with 25% of controls; symptom relief was maintained in follow-up assessments. Additional MDMA research indicates increases in self-compassion, prosocial behaviour and emotionally rich speech in interpersonal tasks. The review emphasises recurring subjective outcome domains across studies: occasioned mystical states, increased openness, improved quality of life, enhanced experiences of love and empathy, and augmented meaning-making capacity. Empathy gains were reported to persist at long-term follow-up in some psilocybin cohorts, and the experience of love and reduced fear in MDMA sessions was linked to improved capacity to address trauma and relational issues. From the literature synthesis, Phelps derives six core therapist competencies. Each is summarised here with its principal components: - Empathetic abiding presence: a calm, composed, mindful, and non-directive empathic stance maintained across preparation, dosing sessions and integration; skills include evenly suspended attention, equanimity, and capacity to ‘‘do by non-doing’’. Personal experience with altered states and contemplative practice are discussed as ways therapists may cultivate this presence. - Trust enhancement: abilities to build interpersonal trust, to foster participants’ trust in their own inner healing capacity, and to normalise paradoxical or challenging session material; includes psychoeducation about expected subjective states and facilitation of multifocal meaning-making. - Spiritual intelligence: an embodied familiarity with mystical and transpersonal states, existential meaning-making, and the capacity to hold and integrate participants’ spiritual claims without premature reduction or dismissal. - Knowledge of the physical and psychological effects of psychedelics: expertise in neurobiology, pharmacology, contraindications, safety procedures, risk assessment and mitigation, set and setting design, and relevant cross-cultural/ceremonial knowledge; the literature also discusses the debated practice of therapists having personal, supervised experience with the medicines. - Therapist self-awareness and ethical integrity: reflective capacity about motives, strong boundary management, awareness of transference–countertransference dynamics, self-care, and adherence to ethical codes (including adaptations from CSP, Usona and other guides). - Proficiency in complementary techniques: competence in a ‘‘toolbox’’ of adjunctive methods (for example somatic techniques such as Holotropic Breathwork, expressive arts, guided imagery and music, narrative/existential approaches, sensorimotor therapies, Internal Family Systems and other modalities) to be used in preparation and integration phases. Phelps also articulates twelve curricular domains intended to structure training programmes. These are presented in the paper as foundational areas for instruction and supervised practice: (1) history and legal status of psychedelic-assisted therapy; (2) neurobiology, neuropharmacology and drug interactions; (3) best practices in set and setting across preparation, session and integration; (4) therapeutic relationship issues including transference, boundaries, ethics and self-care; (5) supervised observation of session videos; (6) variations in therapeutic models (for example client-centred and psycholytic approaches); (7) complementary therapeutic techniques; (8) co-therapy methods and interprofessional team skills; (9) models of consciousness, spiritual intelligence and mystical experience; (10) ceremonial and community uses of psychedelics; (11) supervised clinical internships within FDA-approved trials or expanded access programmes; and (12) personal experience of being guided as a research participant in an FDA-approved study (or regulated experiential alternatives when direct drug experience is not legally or practically available).

Phelps interprets the synthesis as an urgent and practical contribution: with Phase 3 studies and potential expanded-access pathways forthcoming for MDMA and psilocybin, there will be increasing demand for clinicians, clergy and chaplains trained specifically in psychedelic-assisted therapy. The author argues that the six competencies and twelve curricular domains provide a starting framework for curriculum development, program evaluation and philosophical debate about scope of practice. The review situates its proposals relative to earlier research by noting continuity with mid-20th-century clinical observations about desirable therapist qualities (empathy, balance, composure) while underscoring that modern trials' emphasis on manualisation and blinding has limited systematic study of therapist effects. Phelps suggests that some therapist values and behaviours (for example spiritual intelligence and empathic presence) might be particularly relevant given the salutary role of mystical-type experiences in mediating outcomes. Key limitations acknowledged in the extracted text include the sparse and largely anecdotal nature of published material on therapist competencies, the lack of systematic empirical work linking specific therapist skills to outcomes, and legal constraints that historically prevented therapists from gaining personal experience with the medicines outside approved trials. The review also recognizes unresolved practical questions for training programmes: which curricular domains are essential for specific scopes of practice, how trainees should be assessed, and how programme effectiveness should be evaluated. Phelps flags ethical concerns and the need for strong boundary work, supervision and attention to diversity—explicitly noting underrepresentation of women, people of colour and LGBTQ-identified practitioners in current trainings. Implications the author raises are pragmatic and programme-oriented: established training efforts (MAPS, Heffter, Usona, CIIS, GTT) offer models combining didactic, experiential and supervised components; regulatory pathways (e.g. expanded access) will likely necessitate broader training capacity; and empirical research should investigate correlations between therapist competencies, session processes (such as mystical experience and meaning-making) and clinical outcomes. The paper calls for continued development of ethical codes and evaluation frameworks as the field professionalises.

Phelps concludes that psychedelic-assisted psychotherapy has demonstrated substantial clinical promise across multiple outcome domains (symptom reduction, increased meaning-making, empathy and quality of life), but that therapist competencies have been understudied because regulatory demands prioritised control over therapist variability. By compiling six core competencies and twelve curricular domains, the paper offers an initial blueprint for training programmes and a platform for further research, professional debate and refinement. The author suggests that as legal restrictions evolve there is scope for interdisciplinary treatment and retreat centres, expanded access programmes, and larger-scale training efforts to enable wider, ethically grounded clinical application. Finally, Phelps frames this work as both pragmatic and redemptive: preparing therapist guides is essential to realising the potential benefits of psychedelic-assisted therapies while attending to safety, ethics and cultural concerns.